BioNexus Gene Lab Corp (BGLC) director receives 32,258-share fully vested award

Rhea-AI Filing Summary

Yap Chee Keong reported acquisition or exercise transactions in this Form 4 filing.

BioNexus Gene Lab Corp director Yap Chee Keong received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted for completed services under the 2025 Equity Incentive Plan, for no cash consideration, and is held as a direct ownership position of 32,258 shares. For plan purposes, the award was valued at $1.55 per share, equal to the Nasdaq closing price on August 12, 2026.

Insider Trade Summary

Net Buyer: 32,258 shares

Net Buy 1 txn

Insider Yap Chee Keong

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	32,258	--	--

Holdings After Transaction: Common Shares — 32,258 shares (Direct)

Footnotes (1)

1. F1. Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

Key Figures

Shares granted: 32,258 shares Post-transaction holdings: 32,258 shares Plan valuation price: $1.55 per share

3 metrics

Shares granted 32,258 shares Fully vested Other Stock-Based Award granted on August 13, 2026

Post-transaction holdings 32,258 shares Total Common Shares directly owned after the grant

Plan valuation price $1.55 per share Valued for plan purposes at Nasdaq closing price on August 12, 2026

Key Terms

Other Stock-Based Award, 2025 Equity Incentive Plan, Nasdaq closing price

3 terms

Other Stock-Based Award financial

"Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock"

2025 Equity Incentive Plan financial

"granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan"

Nasdaq closing price financial

"valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026)"

FAQ

What did BioNexus Gene Lab Corp (BGLC) report in this Form 4 for Yap Chee Keong?

BioNexus Gene Lab Corp reported that director Yap Chee Keong received a fully vested award of 32,258 Common Shares on August 13, 2026, granted for completed services under the 2025 Equity Incentive Plan and held as a direct ownership position.

How many BGLC shares does Yap Chee Keong hold after this reported transaction?

After the reported grant, 32,258 Common Shares are held directly by Yap Chee Keong. The Form 4 indicates this amount as the total shares owned following the transaction, reflecting the fully vested award granted on August 13, 2026.

What type of transaction is disclosed for BioNexus Gene Lab Corp (BGLC) in this Form 4?

The Form 4 discloses an acquisition by grant/award coded as “A,” representing a fully vested Other Stock-Based Award of 32,258 Common Shares to director Yap Chee Keong, rather than an open-market purchase or sale transaction.

At what price was the BGLC stock award to Yap Chee Keong valued for plan purposes?

For plan purposes, the stock award was valued at $1.55 per share, corresponding to the Nasdaq closing price on August 12, 2026. This valuation was used for the BioNexus Gene Lab Corp 2025 Equity Incentive Plan accounting of the grant.

Did Yap Chee Keong pay cash for the BGLC shares awarded in this Form 4?

No, the 32,258 Common Shares were granted for completed services with no cash consideration. The footnote specifies the award under the 2025 Equity Incentive Plan was compensation in stock, not a cash-funded share purchase.

Is the stock award to Yap Chee Keong under a trading plan such as Rule 10b5-1?

The Form 4’s Rule 10b5-1 checkbox is marked as false, and the footnote describes the transaction as a fully vested stock-based award for completed services, not a trade executed under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:20 PM Accepted by SEC EDGAR 08/14/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yap Chee Keong

(Last) (First) (Middle)

10-2 TOWER B, VERTICAL BUSINESS SUITE

8 JALAN KERINCHI

(Street)

KUALA LUMPUR 59200

(City) (State) (Zip)

MALAYSIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNexus Gene Lab Corp [ BGLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/13/2026		A		32,258	A	(1)	32,258	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

	/s/ Chee Keong Yap	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)